The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

This real-world observational study is tracking the outcomes of women with Stage II or III hormone receptor-positive, HER2-positive early breast cancer who are receiving standard chemotherapy plus HER2-targeted treatment before surgery. The goal is to understand how effective these treatments are in everyday clinical practice. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with Stage II or III hormone receptor-positive, HER2-positive breast cancer - You are planning to receive standard neoadjuvant (pre-surgery) chemotherapy including trastuzumab and pertuzumab - You are in generally good health (Karnofsky score ≥70) - Complete medical records are available **You may NOT be eligible if...** - You have already received any anti-cancer treatment for breast cancer - You are pregnant or breastfeeding - You have Stage IV (metastatic), bilateral, inflammatory, or hidden breast cancer - You have had previous breast cancer treatment Talk to your doctor to see if this trial is right for you.